The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2026 | OPTIMUM: maintenance olaparib ± durvalumab in DDR-mutated advanced BTC
Changhoon Yoo, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses results from the Phase II OPTIMUM study (NCT05222971), which evaluated maintenance olaparib with or without durvalumab in patients with advanced biliary tract cancer (BTC) harboring DDR mutations. Progression-free survival rates were similar between arms, and patients with a core homologous recombination deficiency profile derived notably better outcomes. No new safety signals emerged, supporting further development of homologous recombination deficiency-targeted therapy in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
